Table of Contents:

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size by Vaccine Type

  2.3.2 Market Size by Cancer Type

  2.3.3 Market Size by Technology Platform

  2.3.4 Market Size by Treatment Approach

 2.3.5 Market Size by End-User

 2.4 Market Share & Bps Analysis by Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 Raw Material Suppliers

  3.4.2 Vaccine Development & Manufacturing Companies

  3.4.3 Distribution, Clinical & Healthcare Infrastructure Providers

  3.4.4 End-Users

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

4.1 Cancer Incidence & Precision Oncology Metrics

4.1.1 Share (%) of oncology patients eligible for personalized cancer vaccine therapies based on genomic profiling.

4.1.2 Growth (%) in precision oncology and neoantigen-targeted immunotherapy adoption during 2025 and 2026.

4.1.3 Increase (%) in cancer genome sequencing and biomarker testing procedures globally.

4.2 Vaccine Technology & Clinical Development Metrics

4.2.1 Share (%) of personalized cancer vaccine demand generated by mRNA vaccines, peptide vaccines, dendritic cell vaccines, and DNA-based platforms.

4.2.2 Growth (%) in clinical trials evaluating individualized cancer immunotherapy solutions.

4.2.3 Increase (%) in AI-enabled neoantigen prediction and bioinformatics platform deployment within oncology research.

4.3 Healthcare Infrastructure & Treatment Metrics

4.3.1 Share (%) of personalized cancer vaccine administration occurring through hospitals, specialty cancer centers, and academic research institutes.

4.3.2 Growth (%) in adoption of advanced genomic diagnostics and companion diagnostic technologies.

4.3.3 Increase (%) in demand for ultra-cold chain logistics and biologics handling infrastructure supporting personalized therapies.

4.4 Pharmaceutical & Biotechnology Investment Metrics

4.4.1 Share (%) of oncology R&D investments allocated toward personalized immunotherapy and cancer vaccine development.

4.4.2 Growth (%) in partnerships between biotechnology firms, pharmaceutical companies, and genomic technology providers.

4.4.3 Increase (%) in venture capital and government funding supporting personalized cancer vaccine innovation globally.

4.5 Regulatory & Commercialization Metrics

4.5.1 Share (%) of personalized cancer vaccine candidates progressing through Phase I, II, and III clinical trials.

4.5.2 Growth (%) in regulatory approvals and breakthrough therapy designations for personalized oncology treatments.

4.5.3 Increase (%) in commercialization initiatives for individualized cancer immunotherapies across major healthcare markets.

5. Personalized Cancer Vaccine Market Segmental Analysis & Forecast, By Vaccine Type, 2022–2035, Value (USD Billion)

5.1 Introduction

 5.2 mRNA-Based Vaccines

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.3 Neoantigen-Based Vaccines

 5.4 Dendritic Cell Vaccines

 5.5 Peptide-Based Vaccines

 5.6 Others

6. Personalized Cancer Vaccine Market Segmental Analysis & Forecast, By Cancer Type, 2022–2035, Value (USD Billion)

    6.1 Introduction

 6.2 Melanoma

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 Lung Cancer

 6.4 Breast Cancer

 6.5 Colorectal Cancer

 6.6 Prostate Cancer

 6.7 Others

7. Personalized Cancer Vaccine Market Segmental Analysis & Forecast, By Technology Platform, 2022–2035, Value (USD Billion)

    7.1 Introduction

 7.2 mRNA PCV

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Cell-Based

 7.4 Others

8. Personalized Cancer Vaccine Market Segmental Analysis & Forecast, By Treatment Approach, 2022–2035, Value (USD Billion)

    8.1 Introduction

 8.2 Monotherapy

  8.2.1 Key Trends

  8.2.2 Market Size & Forecast, 2022–2035

 8.3 Combination Therapy

9. Personalized Cancer Vaccine Market Segmental Analysis & Forecast, By End-User, 2022–2035, Value (USD Billion)

    9.1 Introduction 

  9.2 Hospitals

   9.2.1 Key Trends 

   9.2.2 Market Size & Forecast, 2022–2035 

  9.3 Cancer Research Centers

  9.4 Biotechnology and Pharmaceutical Companies

  9.5 Others

10. Personalized Cancer Vaccine Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)

 10.1 Introduction

 10.2 North America

  10.2.1 Key Trends

  10.2.2 Personalized Cancer Vaccine Market Size & Forecast, By Vaccine Type, 2022–2035

  10.2.3 Personalized Cancer Vaccine Market Size & Forecast, By Cancer Type, 2022–2035

  10.2.4 Personalized Cancer Vaccine Market Size & Forecast, By Technology Platform, 2022–2035

  10.2.5 Personalized Cancer Vaccine Market Size & Forecast, By Treatment Approach, 2022–2035

  10.2.6 Personalized Cancer Vaccine Market Size & Forecast, By End-User, 2022–2035

  10.2.7 Personalized Cancer Vaccine Market Size & Forecast, By Country, 2022–2035

   10.2.7.1 USA

   10.2.7.2 Canada

10.3 Europe

 10.3.1 Key Trends

 10.3.2 Personalized Cancer Vaccine Market Size & Forecast, By Vaccine Type, 2022–2035

 10.3.3 Personalized Cancer Vaccine Market Size & Forecast, By Cancer Type, 2022–2035

 10.3.4 Personalized Cancer Vaccine Market Size & Forecast, By Technology Platform, 2022–2035

 10.3.5 Personalized Cancer Vaccine Market Size & Forecast, By Treatment Approach, 2022–2035

 10.3.6 Personalized Cancer Vaccine Market Size & Forecast, By End-User, 2022–2035

 10.3.7 Personalized Cancer Vaccine Market Size & Forecast, By Country, 2022–2035

  10.3.7.1 Germany

  10.3.7.2 UK

  10.3.7.3 France

  10.3.7.4 Italy

  10.3.7.5 Spain

  10.3.7.6 Russia

  10.3.7.7 Poland

  10.3.7.8 Rest of Europe

10.4 Asia-Pacific

 10.4.1 Key Trends

 10.4.2 Personalized Cancer Vaccine Market Size & Forecast, By Vaccine Type, 2022–2035

 10.4.3 Personalized Cancer Vaccine Market Size & Forecast, By Cancer Type, 2022–2035

 10.4.4 Personalized Cancer Vaccine Market Size & Forecast, By Technology Platform, 2022–2035

 10.4.5 Personalized Cancer Vaccine Market Size & Forecast, By Treatment Approach, 2022–2035

 10.4.6 Personalized Cancer Vaccine Market Size & Forecast, By End-User, 2022–2035

 10.4.7 Personalized Cancer Vaccine Market Size & Forecast, By Country, 2022–2035

  10.4.7.1 China

  10.4.7.2 India

  10.4.7.3 Japan

  10.4.7.4 South Korea

  10.4.7.5 Australia

  10.4.7.6 ASEAN Countries

  10.4.7.7 Rest of Asia-Pacific

10.5 Latin America

 10.5.1 Key Trends

 10.5.2 Personalized Cancer Vaccine Market Size & Forecast, By Vaccine Type, 2022–2035

 10.5.3 Personalized Cancer Vaccine Market Size & Forecast, By Cancer Type, 2022–2035

 10.5.4 Personalized Cancer Vaccine Market Size & Forecast, By Technology Platform, 2022–2035

 10.5.5 Personalized Cancer Vaccine Market Size & Forecast, By Treatment Approach, 2022–2035

 10.5.6 Personalized Cancer Vaccine Market Size & Forecast, By End-User, 2022–2035

 10.5.7 Personalized Cancer Vaccine Market Size & Forecast, By Country, 2022–2035

  10.5.7.1 Brazil

  10.5.7.2 Argentina

  10.5.7.3 Mexico

  10.5.7.4 Colombia

  10.5.7.5 Rest of Latin America

10.6 Middle East & Africa

 10.6.1 Key Trends

 10.6.2 Personalized Cancer Vaccine Market Size & Forecast, By Vaccine Type, 2022–2035

 10.6.3 Personalized Cancer Vaccine Market Size & Forecast, By Cancer Type, 2022–2035

 10.6.4 Personalized Cancer Vaccine Market Size & Forecast, By Technology Platform, 2022–2035

 10.6.5 Personalized Cancer Vaccine Market Size & Forecast, By Treatment Approach, 2022–2035

 10.6.6 Personalized Cancer Vaccine Market Size & Forecast, By End-User, 2022–2035

 10.6.7 Personalized Cancer Vaccine Market Size & Forecast, By Country, 2022–2035

  10.6.7.1 UAE

  10.6.7.2 Saudi Arabia

  10.6.7.3 Qatar

  10.6.7.4 South Africa

  10.6.7.5 Rest of Middle East & Africa

11. Competitive Landscape

 11.1 Key Players' Positioning

 11.2 Competitive Developments

  11.2.1 Key Strategies Adopted (%), By Key Players, 2025

  11.2.2 Year-Wise Strategies & Development, 2022 – 2025

  11.2.3 Number Of Strategies Adopted By Key Players, 2025

 11.3 Market Share Analysis, 2025

 11.4 Product/Service & Application Benchmarking

  11.4.1 Product/Service Specifications & Features By Key Players

  11.4.2 Product/Service Heatmap By Key Players

  11.4.3 Application Heatmap By Key Players

 11.5 Industry Start-Up & Innovation Landscape

11.6 Key Company Profiles

 11.6.1 Moderna Inc.

  11.6.1.1 Company Overview & Snapshot

  11.6.1.2 Product/Service Portfolio

  11.6.1.3 Key Company Financials

  11.6.1.4 SWOT Analysis

 11.6.2 BioNTech SE

 11.6.3 Merck & Co. Inc.

 11.6.4 Gritstone Bio Inc.

 11.6.5 Nouscom S.r.l.

 11.6.6 Evaxion Biotech A/S

 11.6.7 CureVac SE

 11.6.8 Immatics N.V.

 11.6.9 NantKwest Inc. (ImmunityBio)

 11.6.10 Personalis Inc.

 11.6.11 Genocea Biosciences Inc.

 11.6.12 ISA Pharmaceuticals BV

 11.6.13 Transgene SA

 11.6.14 Neogene Therapeutics Inc.

 11.6.15 Achilles Therapeutics plc

 11.6.16 Astellia (Novartis)

 11.6.17 OSE Immunotherapeutics

 11.6.18 Agenus Inc.

 11.6.19 Neon Therapeutics (BioNTech)

 11.6.20 Roche Holding AG

12. Analyst Recommendations

 12.1 SNS Insider Opportunity Map

 12.2 Industry Low-Hanging Fruit Assessment

 12.3 Market Entry & Growth Strategy

 12.4 Analyst Viewpoint & Suggestions On Market Growth

13. Assumptions

14. Disclaimer

15. Appendix

 15.1 List Of Tables

 15.2 List Of Figures